We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Circumcision Could Reduce HPV-Associated Penile Precancerous Lesions

By HospiMedica International staff writers
Posted on 15 Aug 2011
A new study shows that among Kenyan men, circumcision is associated with a lower prevalence of human papillomavirus (HPV)-associated precancerous lesions of the penis.

Researchers at the University of North Carolina conducted a randomized controlled trial of male circumcision in Kenya, from May 2006 to October 2007, to examine whether male circumcision may reduce HPV-associated precancerous lesions. More...
The study involved 275 men, of which 151 were circumcised and 124 uncircumcised (median age 22 years). The researchers carried out a visual inspection of the penis using a colposcope at the 24-month visit among the participants, with photos read independently by two observers for quality control. Penile exfoliated cells sampled from the glans, coronal sulcus, and shaft were tested for HPV DNA using a real time polymerase chain reaction (PCR) assay to measure viral loads.

The results showed that circumcised men had a substantially lower prevalence of flat penile lesions (0.7%) compared to uncircumcised men (26.0%). Additionally, compared to men who were HPV negative, men who were HPV DNA positive or who had high HPV16/18/31 viral load had higher odds of flat penile lesions. Among men with flat penile lesions, HPV56 (29%) and HPV16 (25.8%) were the most common types within single or multiple infections. The study was published in the August 2011 issue of the International Journal of Cancer.

“Interventions that reduce HPV-associated penile lesions could be important to both men and women, because such lesions may increase HPV transmission from men to their sexual partners,” said lead author Jennifer Smith, PhD, of the department of epidemiology. “Circumcision may also provide a useful intervention to prevent HPV-associated penile lesions and ultimately invasive cervical cancers in less developed countries, since prophylactic HPV vaccines may not be readily available to men, and current HPV vaccines do not include protection against all high-risk HPV types.”

HPV is a sexually transmitted virus that plays an important role in genital cancers in men and women, including cancers of the penis and cervix. While the majority of the nearly 200 known types of HPV cause no symptoms in most people, some types can cause warts (verrucae), while others can lead to cancers of the cervix, vulva, vagina, and anus in women or cancers of the anus and penis in men. Flat penile lesions are much more frequent in uncircumcised men and associated with higher prevalence of HPV and higher viral loads.

Related Links:
University of North Carolina




Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.